Results 51 to 60 of about 177,775 (151)

Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis

Heliyon
Objective: The primary objective of this paper is to investigate the research hotspots and future trends of immune-related adverse events induced by immune checkpoint inhibitors, offering valuable insights for researchers in this field.
Jun Zhao, Yujie Feng, Guang-wei Liu
doaj   +1 more source

Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade

Nature Communications, 2022
Radiotherapy can activate an in situ vaccine response and promote response to immune checkpoint inhibitors. Here the authors design a multifunctional nanoparticle to enhance tumor antigen presentation and modulate the tumor immune microenvironment ...
Ying Zhang, Raghava N. Sriramaneni, Paul A. Clark, Justin C. Jagodinsky, Mingzhou Ye, Wonjong Jin, Yuyuan Wang, Amber Bates, Caroline P. Kerr, Trang Le, Raad Allawi, Xiuxiu Wang, Ruosen Xie, Thomas C. Havighurst, Ishan Chakravarty, Alexander L. Rakhmilevich, Kathleen A. O’Leary, Linda A. Schuler, Paul M. Sondel, Kyungmann Kim, Shaoqin Gong, Zachary S. Morris   +21 more
doaj   +1 more source

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies

Journal for ImmunoTherapy of Cancer, 2020
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types.
Alberto Puccini, Maria Laura Iaia, Mohamed E Salem   +2 more
doaj   +1 more source

Prospects for combining immune checkpoint blockade with PARP inhibition

Journal of Hematology & Oncology, 2019
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble.
Anping Li, Ming Yi, Shuang Qin, Qian Chu, Suxia Luo, Kongming Wu   +5 more
doaj   +1 more source

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Molecular Therapy: Oncolytics, 2019
Cancer immunotherapy and the emergence of immune checkpoint inhibitors have markedly changed the treatment paradigm for many cancers. They function to disrupt cancer cell evasion of the immune response and activate sustained anti-tumor immunity ...
Venkatesh Sivanandam, Christopher J. LaRocca, Nanhai G. Chen, Yuman Fong, Susanne G. Warner   +4 more
doaj   +1 more source

The Impact of Immune Checkpoint Inhibitors on Fertility Preservation and Pregnancy Outcomes

Journal of Education, Health and Sport
Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing anti-tumor immune responses. However, their impact on fertility is an emerging concern, particularly among young patients, including children.
Agata Prokopiuk, Adrianna Tabeau, Agnieszka Pawlik, Patryk Dudek, Klaudia Łuczak, Wiktoria Ulicka, Justyna Pięta, Hanna Sitarek, Joanna Prus, Marcel Chudzikowski   +9 more
doaj   +1 more source

Anti–PD-1-induced bullous pemphigoid in a renal transplant recipient

SAGE Open Medical Case Reports
Immune checkpoint inhibitors, particularly anti–PD-1 agents, are increasingly associated with bullous pemphigoid, a rare yet significant immune-related adverse event. We report a case of immune checkpoint inhibitor-induced bullous pemphigoid in a 74-year-
Ghassan Barnawi, Abby Johanna Kpata, Raghad Aldibane, Sarah Kashkari, Raquel Lazarowitz, Manish Khanna   +5 more
doaj   +1 more source

Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.

PLoS ONE
BackgroundThe role of upfront cytoreductive nephrectomy remains debatable in the present era of tyrosine kinase inhibitors and immune checkpoint inhibitors.
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

BMC Cancer, 2020
Background We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF.
Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li   +3 more
doaj   +1 more source

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Journal for ImmunoTherapy of Cancer, 2017
Background Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies.
Jose Lutzky, Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka   +5 more
doaj   +1 more source